Executive Editor, Healio Cardiology and Endocrinology
Erik Swain is the Executive Editor at Healio Cardiology and Healio Endocrinology. With a focus on medicine and healthcare, he covers a wide range of topics including endocrinology, health news, and drugs and medication, while also exploring the business, manufacturing, and regulatory aspects of the healthcare industry. Swain's work has been featured in Medical Device and Diagnostic Industry (MDDI) and Healio, and he has received accolades from the APEX Awards for Publication Excellence and the American Society of Healthcare Publication Editors (ASHPE).
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Erik's coverage primarily focuses on scientific and healthcare topics, specifically cardiovascular health, heart conditions, medical research, medications, and treatment options. His articles heavily rely on cited data to support the content.
Given Erik’s focus on scientific and healthcare topics with a reliance on data citations, he would likely be receptive to pitches from experts who can provide in-depth analysis of new medical research findings or breakthroughs in the field of cardiovascular health. Pitches should highlight access to credible data or studies that support their insights.
Since his geographic focus is not specified but the topics covered are universal issues related to healthcare and medicine, sources with expertise in these areas could reach out regardless of location.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Erik Swain
CHICAGO — Major diabetic foot complications were more common in patients with type 2 diabetes treated with SGLT2 inhibitors than those treated with GLP-1 receptor agonists, researchers reported at ENDO 2026.However, new-onset diabetic peripheral neuropathy was lower in patients taking SGLT2 inhibitors compared with those taking GLP-1s, according to the researchers.
By: Richard Smith, Erik Swain
In patients with small aortic annuli undergoing transcatheter aortic valve replacement, a self-expanding supra-annular valve was linked to less
CHICAGO — In patients with acquired hypothalamic obesity, treatment with setmelanotide for 2.5 years was associated with sustained reductions in age-related weight metrics, according to findings from a long-term extension study. The study, presented at ENDO 2026, included 14 participants (12 younger than 18 years) who completed a 16-week phase 2 trial of setmelanotide (Imcivree, Rhythm
By: Erik Swain, Richard Smith
CHICAGO — In patients who received an organ transplant, diabetes — whether diagnosed before or after transplantation — was linked to elevated risk for mortality, researchers reported at ENDO 2026.
By: Erik Swain, Richard Smith, Jill Rollet
Editor's Note: After the June issue of Healio | Endocrine Today went to press, a U.S. district judge voided the H-1B visa fee discussed in this article.
CHICAGO — Most men who received testosterone therapy did not receive a workup in accordance with guidelines, and some received the treatment despite being contraindicated for it, researchers reported at ENDO 2026.
By: Erik Swain, Yehuda Handelsman, Scott Buzby
An update to the previously published multispeciality guide for the management of diabetes, cardiorenal and metabolic diseases will be issued later this year with sweeping updates based on the latest data, a speaker reported.
By: Richard Smith, Erik Swain
CHICAGO — An AI model using electronic health record data helped researchers narrow down who should be screened for primary aldosteronism, according to a poster presented at ENDO 2026.
By: Erik Swain
CHICAGO — In patients with fibrodysplasia ossificans progressiva, an oral selective inhibitor of activin receptor–like kinase 2 was linked to lower odds of new heterotopic ossification lesions vs. placebo at 24 weeks, researchers reported. Interim results of the PROGRESS study, presented at ENDO 2026, included data from 63 patients aged 12 years or older with fibrodysplasia ossificans
By: Richard Smith, Erik Swain
CHICAGO — In a cohort of patients with difficult-to-control type 2 diabetes, approximately one-quarter had hypercortisolism, according to interim results of part 1 of the CAPTAIN-T2D study presented at ENDO 2026.
